

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

**POLLARD, MICHAEL**

2. Address:

601 PENNSYLVANIA AVE., NW SUITE 700, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: MICHAEL POLLARD

Telephone: 2026391884

E-mail (optional): michael\_pollard@medco.com

Senate ID #: 87836-12

House ID #: 36632000

7. Client Name: ☐ Self

**MEDCO HEALTH SOLUTIONS**

### TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): ☒ **OR** Year End (July 1 - December 31): ☐

9. Check if this filing amends a previously filed version of this report: ☐

10. Check if this is a Termination Report: ☐ => Termination Date: 11. No Lobbying Activity: ☐

### INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

#### 12. Lobbying Firms

**INCOME** relating to lobbying activities for this reporting period was:

Less than \$10,000: ☐

\$10,000 or more: ☒ => Income (nearest \$20,000): 110,000.00

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

#### 13. Organizations

**EXPENSES** relating to lobbying activities for this reporting period were:

Less than \$10,000: ☐

\$10,000 or more: ☐ => Expenses (nearest \$20,000): \_\_\_\_\_

#### 14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

- ☐ **Method A.** Reporting amounts using LDA definitions only  
☐ **Method B.** Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  
☐ **Method C.** Reporting amounts under section 162(e) of the Internal Revenue Code

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

S 3 Medicare Prescription Drug Price Negotiation Act of 2007 S 28 Generics First Act of 2007 S 130 Medicare Cost Contract Extension and Refinement Act of 2007 S 137 Preserving Medicare for All Act of 2007 S 158 Access to Affordable Health Care Act S 173 Medicare Health Savings Accounts Act of 2007 S 242 Pharmaceutical Market Access and Drug Safety Act of 2007 S 250 The Medicare Enhancements for Needed Drugs Act of 2007 S 251 Pharmaceutical Market Access Act of 2007 S 273 Prescription Drug and Health Improvement Act of 2007 S 316 Preserve Access to Affordable Generics Act S 355 The Social Security and Medicare Solvency Commission Act S 358 Genetic Information Nondiscrimination Act of 2007 S 468 Food and Drug Administration Safety Act of 2007 S 628 - Critical Access to Health Information Technology Act of 2007 S 976 Genomics and Personalized Medicine Act of 2007 S 885 Community Pharmacy Fairness Act of 2007 S 980 Online Pharmacy Consumer Protection Act of 2007 S 1082 Prescription Drug User Fee Amendments of 2007 S 1108 Medicare Part D Outreach and Enrollment Enhancement Act of 2007 S 1161 Medicare Medical Nutrition Therapy Act of 2007 S 1198 Catastrophic Health Coverage Promotion Act S 1218 Medicare for All Act S 1307 Medicare Provider Accountability Act S 1338 Access to Medicare Imaging Act of 2007 HR 4 Medicare Prescription Drug Price Negotiation Act of 2007 HR 205 Medicare Prescription Drug Enrollment Extension Act of 2007 HR 493 Genetic Information Nondiscrimination Act of 2007 HR 788 Food and Drug Administration Safety Act of 2007 HR 971 Community Pharmacy Fairness Act of 2007 HR 1218 Medicare Prescription Drug Improvement Act HR 1277 Medicare Prescription Drug Benefits Gap Elimination Act of 2007 HR 1282 Medigap Access Improvement Act of 2007 HR 1310 Relief and Elimination of the Medicare Enrollment Deadline Penalty (REMEDY) Act of 2007 HR 1368 Personalized Health Information Act of 2007 HR 1432 Preserve Access to Affordable Generics Act HR 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007 HR 1521 Universal Health Act of 2007: Repeal of the Late Enrollment Penalty in Medicare Part D HR 1666 Health Care Price Transparency Promotion Act of 2007 HR 1902 Protecting Consumer Access to Generic Drugs Act of HR 1952 National Health Information Incentive Act of 2007 HR 1956 Patient Protection and Innovative Biologic Medicines Act of 2007 HR 2009 To repeal the Medicare cost containment provisions contained in subtitle A of title VIII of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. HR 2043 Medicare for All Act HR 2058 Helping Fill the Medicare Rx Gap Act of 2007 HR 2065 Medicare Drug Savings Through Choice Act of 2007 HR 2149 Healthcare Eligibility for Late Participants (HELP) in Medicare Part D Act of 2007 HR 2231 Medicare Access to Complex Rehabilitation and Assistive Technology Act of 2007 HR 2273 Food and Drug Administration Improvement Act of 2007 HR 2307 Preventing Medicare Seniors from being Confused due to Abusive Marketing (Prevent Medicare SCAMs) Act of 2007 HR 2549 . Medicare Secondary Payer and Workers' Compensation Settlement Agreements Act of 2007 HR 2567 Medicare Home Infusion Therapy Coverage Act of 2007 HR 2592 Safe and Effective Drug Development Act of 2007 HR 2606 340B Program Improvement and Integrity Act of 2007 HR 2626 Comprehensive HealthCARE Act of 2007 HR 2827 Medicare Equity and Accessibility Act of 2007 HR 2900 Food and Drug Administration Amendments Act of 2007 HR 2914 Medicare IVIG Access Act of 2007 See next page

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)  
Congressional Budget Office (CBO)  
Federal Trade Commission (FTC)  
Food & Drug Administration (FDA)  
HOUSE OF REPRESENTATIVES  
Health & Human Services, Dept of (HHS)  
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: POLLARD, MICHAEL

Covered Official Position (if applicable): CONSULTANT, FEDERAL POLICY & REGULATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: MMM (one per page)

16. Specific lobbying issues:

S 3 Medicare Prescription Drug Price Negotiation Act of 2007 S 28 Generics First Act of 2007 S 130 Medicare Cost Contract Extension and Refinement Act of 2007 S 137 Preserving Medicare for All Act of 2007 S 158 Access to Affordable Health Care Act S 173 Medicare Health Savings Accounts Act of 2007 S 242 Pharmaceutical Market Access and Drug Safety Act of 2007 S 250 The Medicare Enhancements for Needed Drugs Act of 2007 S 251 Pharmaceutical Market Access Act of 2007 S 273 Prescription Drug and Health Improvement Act of 2007 S 316 Preserve Access to Affordable Generics Act S 355 The Social Security and Medicare Solvency Commission Act S 358 Genetic Information Nondiscrimination Act of 2007 S 468 Food and Drug Administration Safety Act of 2007 S 628 - Critical Access to Health Information Technology Act of 2007 S 976 Genomics and Personalized Medicine Act of 2007 S 885 Community Pharmacy Fairness Act of 2007 S 980 Online Pharmacy Consumer Protection Act of 2007 S 1082 Prescription Drug User Fee Amendments of 2007 S 1108 Medicare Part D Outreach and Enrollment Enhancement Act of 2007 S 1161 Medicare Medical Nutrition Therapy Act of 2007 S 1198 Catastrophic Health Coverage Promotion Act S 1218 Medicare for All Act S 1307 Medicare Provider Accountability Act S 1338 Access to Medicare Imaging Act of 2007 S 1376 340B Program Improvement and Integrity Act of 2007 S 1408 Health Information Technology Act of 2007 S 1505 Affordable Biologics for Consumers Act S 1507 Access to Medicare Data Act of 2007 S 1544 Medicare Quality Enhancement Act of 2007 S 1695 Biologics Price Competition and Innovation Act of 2007 HR 4 Medicare Prescription Drug Price Negotiation Act of 2007 HR 205 Medicare Prescription Drug Enrollment Extension Act of 2007 HR 493 Genetic Information Nondiscrimination Act of 2007 HR 788 Food and Drug Administration Safety Act of 2007 HR 971 Community Pharmacy Fairness Act of 2007 HR 1218 Medicare Prescription Drug Improvement Act HR 1277 Medicare Prescription Drug Benefits Gap Elimination Act of 2007 HR 1282 Medigap Access Improvement Act of 2007 HR 1310 Relief and Elimination of the Medicare Enrollment Deadline Penalty (REMEDY) Act of 2007 HR 1368 Personalized Health Information Act of 2007 HR 1432 Preserve Access to Affordable Generics Act HR 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007 HR 1521 Universal Health Act of 2007: Repeal of the Late Enrollment Penalty in Medicare Part D HR 1666 Health Care Price Transparency Promotion Act of 2007 HR 1902 Protecting Consumer Access to Generic Drugs Act of HR 1952 National Health Information Incentive Act of 2007 HR 1956 Patient Protection and Innovative Biologic Medicines Act of 2007 HR 2009 To repeal the Medicare cost containment provisions contained in subtitle A of title VIII of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. HR 2043 Medicare for All Act HR 2058 Helping Fill the Medicare Rx Gap Act of 2007 HR 2065 Medicare Drug Savings Through Choice Act of 2007 HR 2149 Healthcare Eligibility for Late Participants (HELP) in Medicare Part D Act of 2007 HR 2231 Medicare Access to Complex Rehabilitation and Assistive Technology Act of 2007 HR 2273 Food and Drug Administration Improvement Act of 2007 HR 2307 Preventing Medicare Seniors from being Confused due to Abusive Marketing (Prevent Medicare SCAMs) Act of 2007 HR 2549 . Medicare Secondary Payer and Workers' Compensation Settlement Agreements Act of 2007 HR 2567 Medicare Home Infusion Therapy Coverage Act of 2007 HR 2592 Safe and Effective Drug Development Act of 2007 HR 2606 340B Program Improvement and Integrity Act of 2007 HR 2626 Comprehensive HealthCARE Act of 2007 HR 2827 Medicare Equity and Accessibility Act of 2007 HR 2900 Food and Drug Administration Amendments Act of 2007 HR 2914 Medicare IVIG Access Act of 2007 See next page

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

Congressional Budget Office (CBO)

Federal Trade Commission (FTC)

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: POLLARD, MICHAEL

Covered Official Position (if applicable): CONSULTANT, FEDERAL POLICY AND REGULATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above. **None**

## LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: PHA (one per page)

16. Specific lobbying issues:

S 3 Medicare Prescription Drug Price Negotiation Act of 2007 S 28 Generics First Act of 2007 S 130 Medicare Cost Contract Extension and Refinement Act of 2007 S 137 Preserving Medicare for All Act of 2007 S 158 Access to Affordable Health Care Act S 173 Medicare Health Savings Accounts Act of 2007 S 242 Pharmaceutical Market Access and Drug Safety Act of 2007 S 250 The Medicare Enhancements for Needed Drugs Act of 2007 S 251 Pharmaceutical Market Access Act of 2007 S 273 Prescription Drug and Health Improvement Act of 2007 S 316 Preserve Access to Affordable Generics Act S 355 The Social Security and Medicare Solvency Commission Act S 358 Genetic Information Nondiscrimination Act of 2007 S 468 Food and Drug Administration Safety Act of 2007 S 628 - Critical Access to Health Information Technology Act of 2007 S 976 Genomics and Personalized Medicine Act of 2007 S 885 Community Pharmacy Fairness Act of 2007 S 980 Online Pharmacy Consumer Protection Act of 2007 S 1082 Prescription Drug User Fee Amendments of 2007 S 1108 Medicare Part D Outreach and Enrollment Enhancement Act of 2007 S 1161 Medicare Medical Nutrition Therapy Act of 2007 S 1198 Catastrophic Health Coverage Promotion Act S 1218 Medicare for All Act S 1307 Medicare Provider Accountability Act S 1338 Access to Medicare Imaging Act of 2007 S 1376 340B Program Improvement and Integrity Act of 2007 S 1408 Health Information Technology Act of 2007 S 1505 Affordable Biologics for Consumers Act S 1507 Access to Medicare Data Act of 2007 S 1544 Medicare Quality Enhancement Act of 2007 S 1695 Biologics Price Competition and Innovation Act of 2007 HR 4 Medicare Prescription Drug Price Negotiation Act of 2007 HR 205 Medicare Prescription Drug Enrollment Extension Act of 2007 HR 493 Genetic Information Nondiscrimination Act of 2007 HR 788 Food and Drug Administration Safety Act of 2007 HR 971 Community Pharmacy Fairness Act of 2007 HR 1218 Medicare Prescription Drug Improvement Act HR 1277 Medicare Prescription Drug Benefits Gap Elimination Act of 2007 HR 1282 Medigap Access Improvement Act of 2007 HR 1310 Relief and Elimination of the Medicare Enrollment Deadline Penalty (REMEDY) Act of 2007 HR 1368 Personalized Health Information Act of 2007 HR 1432 Preserve Access to Affordable Generics Act HR 1474 Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007 HR 1521 Universal Health Act of 2007: Repeal of the Late Enrollment Penalty in Medicare Part D HR 1666 Health Care Price Transparency Promotion Act of 2007 HR 1902 Protecting Consumer Access to Generic Drugs Act of HR 1952 National Health Information Incentive Act of 2007 HR 1956 Patient Protection and Innovative Biologic Medicines Act of 2007 HR 2009 To repeal the Medicare cost containment provisions contained in subtitle A of title VIII of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. HR 2043 Medicare for All Act HR 2058 Helping Fill the Medicare Rx Gap Act of 2007 HR 2065 Medicare Drug Savings Through Choice Act of 2007 HR 2149 Healthcare Eligibility for Late Participants (HELP) in Medicare Part D Act of 2007 HR 2231 Medicare Access to Complex Rehabilitation and Assistive Technology Act of 2007 HR 2273 Food and Drug Administration Improvement Act of 2007 HR 2307 Preventing Medicare Seniors from being Confused due to Abusive Marketing (Prevent Medicare SCAMs) Act of 2007 HR 2549 Medicare Secondary Payer and Workers' Compensation Settlement Agreements Act of 2007 HR 2567 Medicare Home Infusion Therapy Coverage Act of 2007 HR 2592 Safe and Effective Drug Development Act of 2007 HR 2606 340B Program Improvement and Integrity Act of 2007 HR 2626 Comprehensive HealthCARE Act of 2007 HR 2827 Medicare Equity and Accessibility Act of 2007 HR 2900 Food and Drug Administration Amendments Act of 2007 HR 2914 Medicare IVIG Access Act of 2007 See next page

17. House(s) of Congress and Federal agencies contacted:

Centers For Medicare and Medicaid Services (CMS)

Congressional Budget Office (CBO)

Federal Trade Commission (FTC)

Food & Drug Administration (FDA)

HOUSE OF REPRESENTATIVES

Health & Human Services, Dept of (HHS)

SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: POLLARD, MICHAEL

Covered Official Position (if applicable): CONSULTANT, FEDERAL POLICY AND REGULATIONS

19. Interest of each foreign entity in the specific issues listed on line 16 above: **None**

Signature: ON FILE Date: Jul 18, 2007

Printed Name and Title: MICHAEL POLLARD, CONSULTANT, FEDERAL POLICY AND RE -

**Information Update Page:**

**Complete ONLY where registration information has changed.**

**LOBBYIST UPDATE**

**23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client**

**ISSUE UPDATE**

**24. General lobbying issues previously reported that NO LONGER pertain**

**AFFILIATED ORGANIZATIONS**

**25. Add the following organization(s)**

**26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client**

**FOREIGN ENTITIES**

**27. Add the following foreign entities**

**28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization**

Signature: ON FILE Date: Jul 18, 2007

Printed Name and Title: -